Afshar, H, Roohafza, H, Mousavi, G, Golchin, S, Toghianifar, N, Sadeghi, M, Talaei, M (2008). Topiramate add-on treatment in schizophrenia: a randomised, double blind, placebo controlled clinical trial. Journal of Psychopharmacology
Andreasen, NC, Carpenter, WT Jr., Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry
Areosa, SA, Sherriff, F, McShane, R (2005). Memantine for dementia. Cochrane Database of Systematic Reviews, Issue 2, CD003154.
Barnett, JH, Robbins, TW, Leeson, VC, Sahakian, BJ, Joyce, EM, Blackwell, AD (2010). Assessing cognitive function in clinical trials of schizophrenia. Neuroscience and Biobehavioral Reviews
Bliss, TV, Collingridge, GL (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature
Bressan, RA, Pilowsky, LS (2000). Imaging the glutamatergic system in vivo – relevance to schizophrenia. European Journal of Nuclear Medicine
Cohen, J (1988). Statistical Power Analysis for the Behavioral Sciences, 2nd edn.
Erlbaum: Hillsdale, NJ.
Day, JC, Wood, G, Dewey, M, Bentall, RP (1995). A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. British Journal of Psychiatry
de Lucena, D, Fernandes, BS, Berk, M, Dodd, S, Medeiros, DW, Pedrini, M, Kunz, M, Gomes, FA, Giglio, LF, Lobato, MI, Belmonte-de-Abreu, PS, Gama, CS (2009). Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. Journal of Clinical Psychiatry
Eckert, S, Diamond, PM, Miller, AL, Velligan, DI, Funderburg, LG, True, JF (1996). A comparison of instrument sensitivity to negative symptom change. Psychiatry Research
Evans, JJ, Chua, SE, McKenna, PJ, Wilson, BA (1997). Assessment of the dysexecutive syndrome in schizophrenia. Psychological Medicine
Farlow, MR, Graham, SM, Alva, G (2008). Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Safety
Feher, EP, Mahurin, RK, Doody, RS, Cooke, N, Sims, J, Pirozzolo, FJ (1992). Establishing the limits of the Mini-Mental State: examination of subtests. Archives of Neurology
Folstein, MF, Folstein, SE, McHugh, PR (1975). ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research
Geerts, H, Grossberg, GT (2006). Pharmacology of acetylcholinesterase inhibitors and N-methyl-d-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. Journal of Clinical Pharmacology
Goff, DC, Keefe, R, Citrome, L, Davy, K, Krystal, JH, Large, C, Thompson, TR, Volavka, J, Webster, EL (2007). Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. Journal of Clinical Psychopharmacology
Green, MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia?
American Journal of Psychiatry
Guy, W (1976). Clinical Global Impression Scale. In ECDEU Assessment Manual for Psychopharmacology, revised edn. (ed. Guy, W.), pp. 218–222. US Department of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research Branch: Rockville, MD.
Hasan, A, Falkai, P, Wobrock, T (2013). Transcranial brain stimulation in schizophrenia: targeting cortical excitability, connectivity and plasticity. Current Medicinal Chemistry
Hasan, A, Falkai, P, Wobrock, T, Lieberman, J, Glenthoj, B, Gattaz, WF, Thibaut, F, Möller, HJ; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia (2012). World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World Journal of Biological Psychiatry
Homayoun, H, Moghaddam, B (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience
Howes, OD, Kapur, S (2009). The dopamine hypothesis of schizophrenia: version III – final common pathway. Schizophrenia Bulletin
Ioannidis, JP (2005). Contradicted and initially stronger effects in highly cited clinical research. Journal of the American Medical Associaton
Javitt, DC, Zukin, SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry
Joshi, I, Yang, Y-M, Wang, L-Y (2007). Cellular/molecular coincident activation of metabotropic glutamate receptors and NMDA receptors (NMDARs) downregulates perisynaptic/extrasynaptic NMDARs and enhances high-fidelity neurotransmission at the developing calyx of the held synapse. Journal of Neuroscience
Kantrowitz, JT, Javitt, DC (2010).
N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?
Brain Research Bulletin
Kay, SR, Fiszbein, A, Opler, LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrernia Bulletin
Kornmeier, J, Sosic-Vasic, Z (2012). Parallels between spacing effects during behavioural and cellular learning. Frontiers in Human Neuroscience
Lee, JG, Lee, SW, Lee, BJ, Park, SW, Kim, GM, Kim, YH (2012). Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investigation
Lesh, TA, Niendam, TA, Minzenberg, MJ, Carter, CS (2011). Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology
Leucht, S, Davis, JM, Engel, RR, Kissling, W, Kane, JM (2009). Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica. Supplementum
Levaux, MN, Potvin, S, Sepehry, AA, Sablier, J, Mendrek, A, Stip, E (2007). Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry
Lieberman, JA, Papadakis, K, Csernansky, J, Litman, R, Volavka, J, Jia, XD, Gage, A; MEM-MD-29 Study Group (2009). A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology
Liemburg, E, Catelein, S, Stewart, R, van der Gaag, M, Aleman, A, Knegtering, H; Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2013). Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. Journal of Psychiatric Research
Little, RJA, Rubin, DB (2002). Statistical Analysis with Missing Data, 2nd edn.
John Wiley: New York.
Lowe, C, Rabbitt, P (1998). Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia
Millan, MJ, Fone, K, Steckler, T, Horan, WP (2014). Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. European Neuropsychopharmacology
Mouchlianitis, E, Bloomfield, MA, Law, V, Beck, K, Selvaraj, S, Rasquinha, N, Waldman, A, Turkheimer, FE, Egerton, A, Stone, J, Howes, OD (2015). Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophrenia Bulletin pii, sbv151.
Muscatello, MR, Bruno, A, De Fazio, P, Segura-Garcia, C, Pandolfo, G, Zoccali, R (2014). Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opinion on Pharmacotherapy
Muscatello, MR, Bruno, A, Pandolfo, G, Micò, U, Bellinghieri, PM, Scimeca, G, Cacciola, M, Campolo, D, Settineri, S, Zoccali, R (2010). Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Journal of Psychopharmacology
Nuechterlein, KH, Green, MF, Kern, RS, Baade, LE, Barch, DM, Cohen, JD, Essock, S, Fenton, WS, Frese, FJ 3rd, Gold, JM, Goldberg, T, Heaton, RK, Keefe, RS, Kraemer, H, Mesholam-Gately, R, Seidman, LJ, Stover, E, Weinberger, DR, Young, AS, Zalcman, S, Marder, SR (2008). The MATRICS consensus cognitive battery, part 1: test selection, reliability and validity. American Journal of Psychiatry
Orellana, G, Slachevsky, A (2013). Executive functioning in schizophrenia. Frontiers in Psychiatry
Overbeek, T, Schruers, K, Griez, E (1999). MINI. Mini International Neuropsychiatric Interview. Dutch version 5.0.0. DSM-IV. University of Maastricht: Maastricht, the Netherlands.
Parsons, CG, Gilling, K (2007). Memantine as an example of a fast, voltage-dependent, open channel N-methyl-d-aspartate receptor blocker. Methods of Molecular Biology
Puangthong, U, Hsiung, GY (2009). Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. Neuropsychiatric Disease and Treatment
Putt, M, Chinchilli, VM (1999). A mixed effects model for the analysis of repeated measures cross-over studies. Statistics in Medicine
Rezaei, F, Mohammad-Karimi, M, Seddighi, S, Modabbernia, A, Ashrafi, M, Salehi, B, Hammidi, S, Motasami, H, Hajiaghaee, R, Tabrizi, M, Akhondzadeh, S (2013). Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology
Schulte, PFJ (2003). What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clinical Pharmacokinetics
Sinclair, D, Adams, CE (2014). Treatment resistant schizophrenia: a comprehensive survey of randomized controlled trials. BMC Psychiatry
Singer, JD, Willett, JB (editors) (2003). Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford University Press: New York.
SPSS Inc. (2014). SPSS Statistics version 22.0.0. SPSS Inc.: Chicago, IL.
Stone, JM, Morrison, PD, Pilowsky, LS (2007). Review: glutamate and dopamine dysregulation in schizophrenia – a synthesis and selective review. Journal of Psychopharmacoly
Tajika, A, Ogawa, Y, Takeshima, N, Hayasaka, Y, Furukawa, TA (2015). Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up. British Journal of Psychiatry
Tanahashi, S, Yamamura, S, Nakagawa, M, Motomura, E, Okada, M (2012). Clozapine, but not haloperidol, enhances glial d-serine and l-glutamate release in rat frontal cortex and primary cultured astrocytes. British Journal of Pharmacology
van Veldhuizen, JR (2007). FACT: a Dutch version of ACT. Community Mental Health Journal
Vayısoğlu, S, Anıl Yağcıoğlu, AE, Yağcıoğlu, S, Karahan, S, Karcı, O, Gürel, SC, Yazıcı, MK (2013). Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophrenia Research
Veerman, SRT, Schulte, PF, Begemann, MJ, de Haan, L (2014
a). Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry
Veerman, SRT, Schulte, PF, Begemann, MJ, Engelsbel, F, de Haan, L (2014
b). Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Pharmacopsychiatry
Veerman, SRT, Schulte, PF, de Haan, L (2014
c). The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry
Ventura, J, Subotnik, KL, Gitlin, MJ, Gretchen-Doorly, D, Ered, A, Villa, KF, Hellemann, GS, Nuechterlein, KH (2015). Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophrenia Research
Wesemann, W, Sontag, KH, Maj, J (1983). Pharmacodynamics and pharmacokinetics of memantine. Arzniemittelforschung
Winblad, B, Jones, RW, Wirth, Y, Stöffler, A, Möbius, HJ (2007). Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dementia and Geriatric Cognitive Disorders
World Medical Association (2013). World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Journal of the American Medical Association
Yeun, EY, Zhong, P, Yan, Z (2010). Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors. Proceedings of the National Academy of Sciences USA
Zoccali, R, Muscatello, MR, Bruno, A, Cambria, R, Micò, U, Spina, E, Meduri, M (2007). The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophrenia Research